Sort
10,766 grants matching “checkpoint inhibitor”
BMT in Solid Tumors
$206,022Kenneth R Cooke · Johns Hopkins University · P01 · FY2020 · CA
BMT in Solid Tumors
$206,022Kenneth R Cooke · Johns Hopkins University · P01 · FY2019 · CA
BMT in Solid Tumors
$206,022Kenneth R Cooke · Johns Hopkins University · P01 · FY2021 · CA
BMT in Solid Tumors
$206,022Kenneth R Cooke · Johns Hopkins University · P01 · FY2022 · CA
(PQ8) Biomarker identification by mass cytometry in peripheral blood of patients with renal cell carcinoma undergoing immune checkpoint therapy
$205,799Wendy Jane Fantl · Stanford University · R21 · FY2019 · CA
PD-1 Blockade and Neoantigen-Specific T Cell Immunity
$205,782Gerald P Linette · University Of Pennsylvania · R21 · FY2016 · CA
DNA MISMATCH REPAIR IN FDURD INDUCED CYTOTOXICITY
$205,734Case Western Reserve University · R01 · FY2001 · CA
Overcoming the immune evasion mechanism of Merkel cell polyomavirus-associated Merkel cell carcinoma
$205,430Jianxin You · University Of Pennsylvania · R21 · FY2021 · AI
Skeletal survivorship and immune therapy: The effects of nivolumab on bone metabolism in renal cell carcinoma
$205,311Kendall Moseley · Johns Hopkins University · R21 · FY2018 · AR
TARGETING ORIGINS OF REPLICATION WITH CANCER DRUGS
$205,284Roswell Park Cancer Institute Corp · R01 · FY2004 · CA
Exploration of the immunosuppressive function of RBMS3/PRRX1 axis in TNBC
$205,187Guojun Wu · Wayne State University · R21 · FY2024 · CA
IMMUNE CHECKPOINT BLOCKADE PROMOTES ADULT T CELL LEUKEMIA
$205,157Lee Ratner · Washington University · R21 · FY2020 · CA
Nanoparticles for In Vivo Labeling of T Cells During Cancer Immunotherapy
$205,144Carlos M Rinaldi-Ramos · University Of Florida · R21 · FY2022 · CA
CHEK2 loss promotes prostate cancer resistance to PARP inhibitors
$205,023Li Jia · Brigham And Women'S Hospital · R21 · FY2023 · CA
GENETICS OF CELL CYCLE &DNA DAMAGE REGULATION IN YEAST
$204,737Baylor College Of Medicine · R01 · FY2001 · GM
Targeting MUC1-C for the Treatment of Small Cell Lung Cancer Progression
$204,707Donald W. Kufe · Dana-Farber Cancer Inst · R21 · FY2023 · CA
THE ROLE OF GADD45 IN G2 - M CHECKPOINT
$204,564University Of Pittsburgh At Pittsburgh · R01 · FY2001 · CA
Noninvasive monitoring of therapeutic response to immune checkpoint inhibitors using circulating exosomes in non-small cell lung cancer
$204,520Sylvia Daunert · University Of Miami School Of Medicine · R21 · FY2024 · CA
Targeting EGFL6 in Ovarian Cancer
$204,372Anil K Sood · University Of Tx Md Anderson Can Ctr · P50 · FY2024 · CA
Targeting uterine serous carcinoma with antibody-drug conjugates
$204,372Anil K Sood · University Of Tx Md Anderson Can Ctr · P50 · FY2024 · CA
Liquid Biopsy Core
$204,368Amir Goldkorn · University Of Southern California · P30 · FY2025 · CA
The prognostic landscape of gender- and ethnicity-specific immune influences on cancer outcomes
$204,233Andrew J. Gentles · Stanford University · R21 · FY2020 · CA
Overcoming Tumor-Intrinsic Therapeutic Resistance to Immunotherapies
$204,106Lewis Zhichang Shi · University Of Alabama At Birmingham · R21 · FY2023 · CA
MDSC-Tumor Crosstalk in Prostate Cancer Progression and Castration Resistance
$204,038Guocan Wang · University Of Tx Md Anderson Can Ctr · R00 · FY2018 · CA
Extracellular Vesicle Core
$204,013Sicheng Wen · Rhode Island Hospital · P30 · FY2025 · GM